In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist

Neuropharmacology

Volumn 115, Issue , 2017, Pages 100-114

  Witkin, Jeffrey M ^a   Ornstein, Paul L ^a   Mitch, Charles H ^a   Li, Renhua ^a   Smith, Stephon C ^a   Heinz, Beverly A ^a   Wang, Xu Shan ^a   Xiang, Chuanxi ^a   Carter, Joan H ^a   Anderson, Wesley H ^a   Li, Xia ^a   Broad, Lisa M ^b   Pasqui, Francesca ^b   Fitzjohn, Stephen M ^b   Sanger, Helen E ^b   Smith, Jodi L ^c   Catlow, John ^a   Swanson, Steven ^a   Monn, James A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Indiana University/Purdue University ^*  (United Kingdom)

^c INDIANA UNIVERSITY   (United States)

Author keywords

LY3020371; Metabotropic glutamate receptors; mGlu2; mGlu3

Indexed keywords

2 AMINO 3 ((3,4 DIFLUOROPHENYL)SULFANYLMETHYL) 4 HYDROXY BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; CALCIUM ION; CYCLIC AMP; FORSKOLIN; GLUTAMIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR ANTAGONIST; POTASSIUM ION; UNCLASSIFIED DRUG; 2-AMINO-3-((3,4-DIFLUOROPHENYL)SULFANYLMETHYL)-4-HYDROXY-BICYCLO(3.1.0)HEXANE-2,6-DICARBOXYLIC ACID HYDROCHLORIDE; AMINO ACID RECEPTOR BLOCKING AGENT; CYCLOHEXANE DERIVATIVE; METABOTROPIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CELL CULTURE; BRAIN SLICE; BRAIN SYNAPTOSOME; BRAIN TISSUE; CALCIUM SIGNALING; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG STRUCTURE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IC50; IN VITRO STUDY; MALE; NONHUMAN; PRIMARY CULTURE; RAT; RECEPTOR BLOCKING; SYNAPTOSOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; CELL LINE; CEREBRAL CORTEX; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84955444406     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.12.021     Document Type: Article

References (105)

1. Ago, Y., Araki, R., Yano, K., Kawasaki, T., Chaki, S., Nakazato, A., Onoe, H., Hashimoto, H., Baba, A., Takuma, K., Matsuda, T., The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice. J. Pharmacol. Sci. 118 (2012), 295–298.
2. 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 65 (2013), 29–38.
3. Alt, A., Nisenbaum, E.S., Bleakman, D., Witkin, J.M., A role for AMPA receptors in mood disorders. Biochem. Pharmacol. 71 (2006), 1273–1288.
4. Anderson, W.W., Collingridge, G.L., Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions. J. Neurosci. 162 (2007), 346–356.
5. Attwell, P.J.E., Koumentaki, A., Croucher, M.J., Bradford, H.F., Specific group II metabotropic glutamate receptor activation inhibits the development of kindled epilepsy in rats. Brain Res. 787 (1998), 286–291.
6. Attwell, P.J.E., Kent, N.S., Jane, D.E., Croucher, M.J., Bradford, H.F., Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine (DCG-IV). Brain Res. 805 (1998), 138–143.
7. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal, J.H., Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47 (2000), 351–354.
8. Bueno, A.B., Collado, I., de Dios, A., Dominguez, C., Martin, J.A., Martin, L.M., Martinez-Grau, M.A., Montero, C., Pedregal, C., Catlow, J., Coffey, D.S., Clay, M.P., Dantzig, A.H., Lindstrom, T., Monn, J.A., Jiang, H., Schoepp, D.D., Stratford, R.E., Tabas, L.B., Tizzano, R.A., Herin, M.F., Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J. Med. Chem. 48 (2005), 5305–5320.
9. 2/3 receptor agonists, LY354740 and LY379268, selectively attenuate phencyclidine versus d-amphetamine motor behavior in rats. J. Pharmacol. Exp. Ther. 291 (1999), 161–170.
10. Cartmell, J., Monn, J.A., Schoepp, D.D., The mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur. J. Pharmacol. 400 (2000), 221–224.
11. Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., Nakanishi, S., Nakazato, A., MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46 (2004), 457–467.
12. 2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 66 (2013), 40–52.
13. Chappell, M.D., Li, R., Smith, S.C., Dressman, B.A., Tromiczak, E.G., Tripp, A.E., Blanco, M.J., Vetman, T., Quimby, S.J., Matt, J., Britton, T.C., Fivush, A.M., Schkeryantz, J.M., Khilevich, A., Jaramillo, C., Carpintero, M., de Diego, J.E., Barberis, M., Garcia, S., Soriano, J.F., Witkin, J.M., Li, X., Overshiner, C., Wafford, K.A., Seidel, W., Wang, X., Heinz, B.A., Swanson, S., Catlow, J., Bedwell, D., Ornstein, P.L., Mitch, C.H., Discovery, synthesis, and characterization of a potent antagonist of the metabotropic glutamate 2/3 receptors possessing anti-depressant and wake-promoting properties. Abstracts of Papers for the 248th Meeting of the American Chemical Society, August 10–14, San Francisco, CA, 2014 MEDI-291.
14. Chen, H.D., Jin, Z.L., Zhang, L.M., Xue, R., Xu, X.D., Zhao, N., Qiu, Z.K., Wang, X.W., Zhang, Y.Z., Yang, R.F., Li, Y.F., Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist. PLoS One, 8, 2013, e83271.
15. Dietrich, D., Kral, T., Clusmann, H., Friedl, M., Schramm, J., Presynaptic group II metabotropic glutamate receptors reduce stimulated and spontaneous transmitter release in human dentate gyrus. Neuropharmacology 42 (2002), 297–305.
16. Dominguez, C., Prieto, L., Valli, M.J., Massey, S.M., Bures, M., Wright, R.A., Johnson, B.G., Andis, S.L., Kingston, A., Schoepp, D.D., Monn, J.A., Methyl substitution of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: Identification of a subtype selective mGlu2 receptor agonist. J. Med. Chem. 48 (2005), 3605–3612.
17. Downing, A.M., Kinon, B.J., Millen, B.A., Zhang, L., Liu, L., Morozova, M.A., Brenner, R., Rayle, T.J., Nisenbaum, L., Zhao, F., Gomez, J.C., A double blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psych., 14, 2014, 10.1186/s12888-014-0351-3 in press.
18. Du, J., Zhou, S., Carlton, S.M., Group II metabotropic glutamate receptor activation attenuates peripheral sensitization in inflammatory states. Neuroscience 154 (2008), 754–766.
19. Duman, R.S., Li, N., Liu, R.J., Duric, V., Aghajanian, G., Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62 (2012), 35–41.
20. Dunayevich, E., Erickson, J., Levine, L., Landbloom, R., Schoepp, D.D., Tollefson, G.D., Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacol 33 (2008), 1603–1610.
21. 2/3 blockade. Int. J. Neuropsychopharmacol. 15 (2012), 429–434.
22. Fabricius, K., Helboe, L., Fink-Jensen, A., Wortwein, G., Steiniger-Brach, B., Pharmacological characterization of social isolation-induced hyperactivity. Psychopharmacol 215 (2011), 257–266.
23. 2/3 receptor agonist LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats. J. Pharmacol. Exp. Ther. 312 (2005), 826–833.
24. 2/3 receptor antagonist, in healthy human subjects. Abstracts of papers Soc Neurosci., 2012 New Orleans, LA, abstract 841.20.
25. Gatti, S., Goetschi, E., Palmer, W.S., Wichmann, J., Woltering, T.J., 2006. Preparation of acetylenyl-pyrazolo-pyrimidine derivatives for use a mGluR2 antagonists treating CNS disorders. PCT Int. Appl. WO2006099972 A1.
26. Goeldner, C., Ballard, T.M., Knoflach, F., Wichmann, J., Gatti, S., Umbricht, D., Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology 64 (2013), 337–346.
27. Gu, G., Lorrain, D.S., Wei, H., Cole, R.L., Zhang, X., Daggett, L.P., Schaffhauser, H., Bristow, L.J., Lechner, S.M., Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition. Brain Res. 1197 (2008), 47–62.
28. Hashimoto, K., Malchow, B., Falkai, P., Schmitt, A., Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 263 (2013), 367–377.
29. Helton, D.R., Tizzano, J.P., Monn, J.A., Schoepp, D.D., Kallman, M.J., Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284 (1998), 651–660.
30. Iacovelli, L., Molionaro, G., Battaglia, G., Motolese, M., Di Menna, L., Alfiero, M., Blahos, J., Matrisciano, F., Corsi, M., Corti, C., Bruno, V., De Blasi, A., Nicoetti, F., Regulation of group II metabotropic glutamate receptors by G-protein-coupled receptor kinases: mGlu2 receptors are resistant to homologous desensitization. Mol. Pharmacol. 75 (2009), 991–1003.
31. Iadarola, N.D., Niciu, M.J., Richards, E.M., Vande Voort, J.L., Ballard, E.D., Lundin, N.B., Nugent, A.C., Machado-Vieira, R., Zarate, C.A. Jr., Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther. Adv. Chronic Dis. 6 (2015), 97–114.
32. Jensen, A.A., Fahlke, C., Bjorn-Yoshimoto, W., Bunch, L., Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities. Curr. Opin. Pharmacol. 20 (2015), 116–123.
33. Jones, C.K., Lutz Eberle, E., Peters, S.C., Monn, J.A., Shannon, H.E., Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology 49 (2005), 206–218.
34. Jones, C.A., Brown, A.M., Auer, D.P., Fone, K.C.F., The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacolgy 214 (2011), 269–283.
35. Karasawa, J., Shimazaki, T., Kawashima, N., Chaki, S., AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 1042 (2005), 92–98.
36. Kew, J.N.C., Ducarre, J.-M., Pflimlin, M.-C., Mutel, V., Kemp, J.A., Activity-dependent presynaptic autoinhibition by group II metabotropic glutamate receptors at the perforant path inputs to the dentate gyrus and CA1. Neuropharmacology 40 (2001), 20–27.
37. Kew, J.N.C., Pflimlin, M.-C., Kemp, J.A., Mutel, V., Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -/- mice. Neuropharmacology 42 (2002), 215–221.
38. Kilbride, J., Huang, L., Rowan, M.J., Anwyl, R., Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists LY354740 and DCG-IV. Eur. J. Pharmacol. 356 (1998), 149–157.
39. Kim, S.H., Steele, J.W., Lee, S.W., Clemenson, G.D., Carter, T.A., Treuner, K., Gadient, R., Wedel, P., Glabe, C., Barlow, C., Ehrlich, M.E., Gage, F.H., Gandy, S., Proneurogenic group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse. Mol. Psychiatry 19 (2014), 1235–1242.
40. Kingston, A.E., Ornstein, P.L., Wright, R.A., Johnson, B.G., Mayne, N.G., Burnett, J.P., Belagaje, R., Wu, S., Schoepp, D.D., LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37 (1998), 1–12.
41. 2/3 agonist pomaglumetad methionil in schizophrenia. Biol. Psych., 2015, 10.1016/j.biopsych.2015.03.016 in press.
42. Kłodzińska, A., Chojnacka-Wójcik, E., Pałucha, A., Brański, P., Popik, P., Pilc, A., Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38 (1999), 1831–1839.
43. 2+ spikes by metabotropic glutamate receptors in primary cultures of rat cortical neurons. J. Neurosci. Res. 88 (2010), 2252–2262.
44. Koike, H., Chaki, S., Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav. Br. Res. 271 (2014), 111–115.
45. Kumar, N., Laferriere, A., Yu, J.S.C., Poon, T., Coderre, T.J., Metabotropic glutamate receptors (mGluRs) regulate noxious stimulus-induced glutamate release in the spinal cord dorsal horn of rats with neuropathic and inflammatory pain. J. Neurochem. 114 (2010), 281–290.
46. 2]. Dean, D.C., Filer, C.N., McCarthy, K.E., (eds.) Synthesis and Applications of Isotopically Labeled Compounds Proceedings of the International Symposium, vol. 8, 2003, John Wiley and Sons, Ltd., Chichester, UK, 267–270.
47. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
48. Lin, J.H., CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr. Drug Metab. 9 (2008), 46–59.
49. ++ channels and endogenous dopamine. Mol. Cell. Neurosci. 31 (2006), 284–292.
50. Mercer, M.S., Lodge, D., Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential. Neurochem. Res. 39 (2014), 1876–1894.
51. Moghaddam, B., Adams, B.W., Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Science 281 (1998), 1349–1352.
52. 2/3-mediated cAMP potentiation is calcium sensitive: studies in murine neuronal and astrocyte cultures. Neuropharmacology 43 (2002), 189–203.
53. Monn, J.A., Valli, M.J., Massey, S.M., Wright, R.A., Salhoff, C.R., Johnson, B.G., Howe, T., Alt, C.A., Rhodes, G.A., Robey, R.L., Griffey, K.R., Tizzano, J.P., Kallman, M.J., Helton, D.R., Schoepp, D.D., Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 40 (1997), 528–537.
54. Monn, J.A., Valli, M.J., Massey, S.M., Hansen, M.M., Kress, T.J., Wepsiec, J.P., Harkness, A.R., Grutsch, J.L. Jr., Wright, R.A., Johnson, B.G., Andis, S.L., Kingston, A.E., Tomlinson, R., Lewis, R., Griffey, K.R., Tizzano, J.P., Schoepp, D.D., Synthesis, pharmacological characterization and molecular modeling of heterobicyclic amino acids related to LY354740: Identification of LY379268 and LY389795: two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. 42 (1999), 1027–1040.
55. 2/3 receptors. J. Med. Chem. 50 (2007), 233–240.
56. Monn, J.A., Witkin, J.M., Ornstein, P.L., Mitch, C.H., Li, R., Smith, S.C., Wang, X., Xiang, C., Carter, J.H., Wang, J., Atwell, S., Pasqui, F., Fitzjohn, S., Heinz, B.A., In vitro attributes of LY3020371, a potent and selective mGlu2/3 receptor antagonist. Abstracts of Papers for the 8th International Meeting on Metabotropic Glutamate Receptors, September 27-October 3, 2014, Taormina, Sicily, Italy Curr. Neuropharmacol., 12(Suppl. 1), 2014, 43.
57. Monn, J.A., Prieto, L., Taboada, L., Hao, J., Reinhard, M.R., Henry, S.S., Beadle, C., Walton, L., Man, T., Rudyk, H., Clark, B., Tupper, D., Baker, S.R., Lamas, C., Montero, C., Marcos, A., Blanco, J., Bures, M., Clawson, D.K., Atwell, S., Lu, F., Wang, J., Russell, M., Heinz, B., Wang, X., Carter, J., Getman, B., Catlow, J., Swanson, S., Sanger, H., Broad, L.M., Johnson, B.G., Shaw, D., McKinzie, D.L., Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: Identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures. J. Med. Chem. 58 (2015), 1776–1794.
58. Monn, J.A., Prieto, L., Taboada, L., Hao, J., Reinhard, M.R., Henry, S.S., Beadle, C., Walton, L., Man, T., Rudyk, H., Clark, B., Tupper, D., Baker, S.R., Lamas, C., Montero, C., Marcos, A., Blanco, J., Bures, M.G., Clawson, D.K., Atwell, S., Lu, F., Wang, J., Russell, M., Heinz, B.A., Wang, X., Carter, J., Getman, B., Catlow, J., Swanson, S., Johnson, B.G., Shaw, D., McKinzie, D.L., Synthesis and pharmacological characterization of C4-(thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. In vitro and in vivo evidence of a highly potent, functionally selective mGlu2 receptor agonist. J. Med. Chem., 2015, 10.1021/acs.jmedchem.5b01124 in press.
59. 2+ transients in cultures cortical neurons. J. Neurosci. 12 (1992), 4834–4845.
60. Musgrave, M.A., Midigan, M.A., Bennett, B.M., Goh, J.W., Stimulation of postsynaptic and inhibition of presynaptic adenylyl cycloase activity by metabotropic glutamate receptor activation. J. Neurochem. 62 (1994), 2316–2324.
61. Nakamura, M., Kawakita, Y., Yasuhara, A., Fukasawa, Y., Yoshida, K., Sakagami, K., Nakazato, A., In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of MSG0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid), a potent metabotropic glutamate receptor antagonist. Drug Metab. Disp. 34 (2006), 369–374.
62. Nakazato, A., Kumagai, T., Sakagami, K., Yoshikawa, R., Suzuki, Y., Shigeyuki, C., Ito, H., Taguchi, T., Nakanishi, S., Okuyama, S., Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J. Med. Chem. 43 (2000), 4893–4909.
63. Nakazato, A., Sakagami, K., Yasuhara, A., Ohta, H., Yoshikawa, R., Itoh, M., Nakamura, M., Chaki, S., Synthesis, in vitro pharmacology, structure-activity relationships and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J. Med. Chem. 47 (2004), 4570–4587.
64. Neki, A., Ohishi, H., Kaneko, T., Shigemoto, R., Nakanishi, S., Mizuno, N., Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody. Neurosci. Lett. 202 (1996), 197–200.
65. Neugebauer, V., Chen, P.-S., Willis, W.D., Groups II and III metabotropic glutamate receptors differentially modulate brief and prolonged nociception in primate SST cells. J. Neurophys. 84 (2000), 2998–3009.
66. 35S]thio)triphosphate binding assay. Basic Clin. Pharmacol. Toxicol. 109 (2011), 175–185.
67. Ornstein, P.L., Bleisch, T.J., Arnold, M.B., Wright, R.A., Johnson, B.G., Schoepp, D.D., 2-Substituted 2SR-2-amino-2-(1SR,2SR-2-carboxycyclopropan-1-yl)glycines as potent and selective antagonists of group 2 metabotropic glutamate receptors: Part 1; effects of alkyl, arylalkyl and diarylalkyl substitution. J. Med. Chem. 41 (1998), 346–357.
68. Ornstein, P.L., Bleisch, T.J., Arnold, M.B., Wright, R.A., Johnson, B.G., Tizzano, J.P., Helton, D.R., Kallman, M.J., Schoepp, D.D., 2-Substituted 2SR-2-amino-2-(1SR,2SR-2-carboxycyclopropan-1-yl)glyc ines as potent and selective antagonists of group 2 metabotropic glutamate receptors: Part 2; effects of aromatic substitution: pharmacological characterization and bioavailability. J. Med. Chem. 41 (1998), 358–378.
69. Pałucha-Poniewiera, A., Wierońska, J.M., Brański, P., Stachowicz, K., Chaki, S., Pilc, A., On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Neuropharmacololgy 212 (2010), 523–535.
70. 2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13 (2007), 1103–1108.
71. Perkins, E.J., Abraham, T., Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity. Drug Metab. Disp. 35 (2007), 1903–1909.
72. Petralia, R.S., Wang, Y.-X., Niedzielski, A.S., Wenthold, R.J., The metabotropic glutamate receptors mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71 (1996), 949–976.
73. Pin, J.-P., Duvoisin, R., Review: neurotransmitter receptors I. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 (1995), 1–26.
74. Reisberg, B., Doody, R., Stӧffler, A., Schmitt, F., Ferris, S., Mobius, H.J., Menantine Study Group, Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348 (2003), 1333–1341.
75. 35S]GTPγS binding. J. Comp. Neurol. 487 (2005), 15–27.
76. Robinson, H.P.C., Kawahara, M., Jimbo, Y., Kuroda, Y., Torimitsu, K., Kuroda, Y., Kawana, A., Periodic synchronized bursting and intracellular calcium transients elicited by low magnesium in cultured cortical neurons. J. Neurophysiol. 70 (1993), 1606–1616.
77. 2/3 ligands and activated by N-acetylaspartylglutamate (NAAG). Neuropharmacology 66 (2013), 311–316.
78. 2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J. Pharmacol. Exp. Ther. 316 (2006), 905–913.
79. 2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacol 193 (2007), 121–136.
80. Sanger, H., Hanna, L., Colvin, E.M., Grubisha, O., Ursu, D., Heinz, B.A., Findlay, J.D., Vivier, R.G., Sher, E., Lodge, D., Monn, J.A., Broad, L.M., Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR. Neuropharmacology 66 (2013), 264–273.
81. Schaffhauser, H., Cartmell, J., Jacob-Rotne, R., Mutel, V., Pharmacological characterization of metabotropic glutamate receptors linked to the inhibition of adenylate cyclase activity in rat striatal slices. Neuropharmacology 36 (1997), 933–940.
82. Schoepp, D.D., Johnson, B.G., Salhoff, C.R., Valli, M.J., Desai, M.A., Burnett, J.P., Mayne, N.G., Monn, J.A., Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate. Neuropharmacology 34 (1995), 843–850.
83. Schoepp, D.D., Johnson, B.G., Wright, R.A., Salhoff, C.R., Monn, J.A., Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+) LY354740, a novel group II metabotropic glutamate receptor agonist. Schmiedeb. Arch. Pharmacol. 358 (1998), 175–180.
84. 2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6 (2003), 189–197.
85. Shvarts, V., Chung, S., Perampanel: newly approved, novel antiepileptic medication for partial onset seizures. Exp. Rev. Neurother. 13 (2013), 131–134.
86. Simmons, R.M.A., Webster, A.A., Kalra, A.B., Iyengar, S., Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol. Biochem. Behav. 73 (2002), 419–427.
87. Smith, S.C., Li, R., Mitch, C.H., Vetman, T. N., 2012. 4-Substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane Compounds as mGluR 2/3 Antagonists. Int. Pat. Appl. WO 2012/0680678.
88. Steffens, M., Zentner, J., Honegger, J., Feuerstein, T.J., Binding affinity and agonist activity of putative endogenous cannabinoids at the human neorcortical CB1 receptor. Biochem. Pharmacol. 69 (2005), 169–178.
89. Stocchi, F., Rascol, O., Destee, A., Hattori, N., Hauser, R.A., Lang, A.E., Poewe, W., Stacy, M., Tolosa, E., Gao, H., Nagel, J., Merschhemke, M., Graf, A., Kenney, C., Trenkwalder, C., AFQ056 in parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. 28 (2013), 1838–1846.
90. Swanson, C.J., Bures, M., Johnson, M.P., Linden, A.M., Monn, J.A., Schoepp, D.D., Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4 (2005), 131–144.
91. Takamori, K., Hirota, S., Chaki, S., Tanaka, M., Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci. 73 (2003), 1721–1728.
92. Traynelis, S.F., Wollmuth, L.P., McBain, C.J., Menniti, F.S., Vance, K.M., Ogden, K.K., Hansen, K.B., Yuan, H., Myers, S.J., Dingledine, R., Glutamate receptor inon channels: structure, regulation, and function. Pharmacol. Rev. 62 (2010), 405–496.
93. Umbricht, D., Niggli, M., Sanwald-Ducray, P., Deptula, D., Moore, R., Grünbauer, W., Boak, L., Gatti, S., Fontoura, P., A Double-blind, Placebo-controlled Study of the Antidepressant Effects of the mGlu2 Negative Allosteric Modulator Rg1578 in Patients with Inadequate Response to Antidepressant Therapy. Abstracts of Papers, Society of Biological Psychiatry, May 14–16, 2015, Fairmont Royal York, Toronto, Canada.
94. 2+ oscillations in cortical neurons. Brain Res. 767 (1997), 239–249.
95. Whittaker, V.P., Michaelson, J.A., Kirkland, R.J., The separation of synaptic vesicles from nerve-ending particles (‘synaptosomes’). Biochem. J. 90 (1964), 293–303.
96. Whittaker, V.P., Thirty years of synaptosome research. J. Neurocytol. 22 (1993), 735–742.
97. Witkin, J.M., Eiler, W.J.A., Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders. Drug Dev. Res. 67 (2006), 757–769.
98. Witkin, J.M., Marek, G.J., Johnson, B.J., Schoepp, D.D., Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol. Disord. Drug Targets 6 (2007), 87–100.
99. 2/3 receptor antagonist. Abstracts of Papers for the 8th International Meeting on Metabotropic Glutamate Receptors, September 27-October 3rd, Taormina, Sicily, Italy Curr. Neuropharmacol., 12(Suppl. 1), 2014, 62.
100. 2/3 antagonists. Biomed. Chem. Lett. 20 (2010), 6969–6974.
101. Wright, R.A., Johnson, B.G., Zhang, C., Salhoff, C., Kingston, A.E., Calligaro, D.O., Monn, J.A., Schoepp, D.D., Marek, G.J., CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [3H]LY459477 autoradiography. Neuropharmacology 66 (2013), 89–98.
102. Yasuhara, A., Nakamura, M., Sakagami, K., Shimazaki, T., Yoshikawa, R., Chaki, S., Ohta, H., Nakazato, A., Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg. Med. Chem. 14 (2006), 4193–4207.
103. Yoshimizu, T., Chaki, S., Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem. Biophys. Res. Commun. 315 (2004), 493–496.
104. 2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacol 186 (2006), 587–593.
105. Zarate, C.A., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., Manji, H.K., A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63 (2006), 856–864.